https://orcid.org/0000-0002-6562-7686
References
- World Health Organization . Global tuberculosis report. Licence: CC BY-NC-SA 3.0 IGOGeneva (2020). http://www.who.int/tb/publications/global_report/en/
- Mehra M , CossrowN , KambiliC , UnderwoodR , MakkarR , PotluriR. Assessment of tuberculosis burden in China using a dynamic disease simulation model. Int. J. Tuberc. Lung Dis.17(9), 1186–1194 (2013).
- Law S , PiatekAS , VincentC , OxladeO , MenziesD. Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. Lancet Public Health2(1), e47–e55 (2017).
- Trauer JM , DenholmJT , McBrydeES. Construction of a mathematical model for tuberculosis transmission in highly endemic regions of the Asia-Pacific. J. Theor. Biol.358, 74–84 (2014).
- Uplekar M , WeilD , LonnrothKet al. WHO's new end TB strategy. Lancet385(9979), 1799–1801 (2015).
- Yang P , SongY , XiaX , ZhangAM. Rapid screening mutations of first line-drug-resistant genes in Mycobacterium tuberculosis strains by allele-specific real-time quantitative PCR. PeerJ7, e6696 (2019).
- Cegielski JP , KurbatovaE , vander Walt Met al. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin. Infect. Dis.62(4), 418–430 (2016).
- Dong K , PanH , YangDet al. Induction, detection, formation, and resuscitation of viable but non-culturable state microorganisms. Compr. Rev. Food Sci. Food Saf.19(1), 149–183 (2020).
- Saito K , WarrierT , Somersan-KarakayaSet al. Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations. Proc. Natl Acad. Sci. USA114(24), e4832–e4840 (2017).
- Hu Y , LiuA , Ortega-MuroFet al. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front. Microbiol.6(641), 1–10 (2015).
- Sulis G , PaiM. Isoniazid-resistant tuberculosis: a problem we can no longer ignore. PLoS Med.17(1), e10030232020 (2020).
- World Health Organization . Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. (2013). https://apps.who.int/iris/handle/10665/112472
- Kendall EA , SahuS , PaiMet al. What will it take to eliminate drug-resistant tuberculosis? Int. J. Tuberc. Lung Dis. 23(5), 535–546 (2019).
- Cazabon D , PandeT , KikSet al. Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: a trend analysis from 2014–2016. Gates Open Res.2, 35 (2018).
- Talbot EA , PaiM. Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations. Int. J. Tuberc. Lung Dis.23(7), 774–782 (2019).
- World Health Organization . WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Licence: CC BY-NC-SA 3.0 IGOGeneva (2018). http://www.who.int/tb/publications/2018/WHO_guidelines_isoniazid_resistant_TB/en/
- Fregonese F , AhujaSD , AkkermanOWet al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir. Med.6(4), 265–275 (2018).
- Nahid P , MaseSR , MiglioriGBet al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am. J. Respir. Crit. Care Med.200(10), e93–e142 (2019).
- World Health Organization . Implementing the end TB strategy: the essentials (2015). http://www.who.int/tb/publications/2015/The_Essentials_to_End_TB/en/
- Furin J , LovedayM , HlanguSet al. “A very humiliating illness”: a qualitative study of patient-centered care for rifampicin-resistant tuberculosis in South Africa. BMC Public Health20(1), 76 (2020).